1.Carotid artery stenting or carotid endarterectomy for treatment of carotid stenosis:Effectiveness and safety
Hai XIN ; Chao BAI ; Yang WANG ; Xinxi LI ; Jun LUO ; Ye TIAN ; Kerui ZHANG
Chinese Journal of Tissue Engineering Research 2013;(51):8920-8927
BACKGROUND:Large randomized trials have demonstrated carotid endarterectomy or stenting for symptomatic and asymptomatic extracranial carotid stenosis is effective.
OBJECTIVE:Using the meta analysis method, to evaluate efficacy and safety of carotid stenting and carotid endarterectomy for the treatment of carotid stenosis.
METHODS:Computer-based retrieval of databases both at home and abroad was performed for randomized control ed trials related to carotid stenting and carotid endarterectomy for the treatment of carotid stenosis. According to exclusion criteria, literature screening was done fol owed by quality evaluation. Then, the enrol ed literatures were analyzed by Cochrane col aboration with RevMan5.0 Meta analysis software.
RESULTS AND CONCLUSION:There were 14 enrol ed studies, including 7 693 patients among whom, 3 835 cases were in stenting group and 3 858 in carotid endarterectomy group. Compared with the carotid endarterectomy group, the stroke event rate within 30 days postoperatively, death and stroke event rate within 30 days postoperatively, myocardial infarction event rate within 1 year postoperatively and non-disabling stroke event rate within 30 days postoperatively were higher in the stenting group (P ≤0.000 1);the myocardial infarction event rate within 30 days postoperatively was lower in the stenting group (P=0.001 0). There were no significant differences in the death event rate and disabled stroke event rate within 30 days postoperatively between the two groups. These two treatments are complementary rather than antagonistic. We should optimize the treatment choice based on the comprehensive analysis of each patient's condition.
2.Application effect of different peritoneal dialysis fluid collection methods for pathogenic bacteria culture in peritonitis dialysis-associated peritonitis
Miaojuan XU ; Qianwen ZHU ; Kerui WANG
Chinese Journal of Modern Nursing 2018;24(10):1195-1198
Objective To evaluate three different peritoneal dialysis fluid collection methods for pathogenic bacteria culture in peritonitis dialysis-associated peritonitis (PDAP), and provide clinical basis for the use of simple and effective peritoneal dialysis fluid collection method in primary hospital. Methods A total of 32 cases of PDAP patients treated in Shulan (Hangzhou) Hospital from June 2016 to July 2017 were included in the study using convenient sampling method. A number of 43 peritoneal dialysis fluid specimens were collected respectively using the traditional method, modified method and centrifugal method, and then were cultured for bacterial identification. Positive rate of bacteria, distribution of bacterial pathogens and reported time were compared among three groups. Results The positive rate of pathogenic bacteria showed that traditional method was 53.5%, modified method was 76.7% and centrifugal method was 83.7%. Compared with the traditional method, the positive rate of modified method and centrifugal method increased significantly (P<0.05). However, there was no statistical difference between the modified method and centrifugal method (P> 0.05). Three main species were epidermis staphylococcus, escherichia coli and staphylococcus aureus in three collection methods. In the modified method and centrifugal method, the positive rate of gram negative bacteria were higher than the traditional method (P<0.05); but there was no obvious difference on the positive rate of gram positive bacteria culture (P>0.05). The average reporting time of traditional culture was longer than the modified method and centrifugal method (P< 0.05). Conclusions Compared with traditional collection method, both modified method and centrifugal method could increase positive rate of bacteria culture in PDAP patients, especially gram negative bacteria, and had the advantage of rapid detection, which could provide clinical guidance for early treatment of peritonitis. Compared with centrifugal method, the modified method is simple, and worthy of promoting in primary hospital.
3.Clinical comprehensive evaluation of three oral Janus kinase inhibitors for atopic dermatitis
Kerui YIN ; Ziyang WU ; Wanqing WANG ; Yongfu HANG ; Zihan WANG ; Jingjing ZHANG ; Jianguo ZHU
China Pharmacy 2024;35(12):1419-1425
OBJECTIVE To comprehensively evaluate the three oral Janus kinase inhibitors (JAKi) such as upadacitinib, abrocitinib and baricitinib in the treatment of atopic dermatitis. METHODS The six dimensions of safety, efficacy, economy, appropriateness, accessibility and innovativeness were used for evaluation. Meta-analysis was conducted to evaluate the safety and efficacy of three oral JAKi; pharmacoeconomic studies were searched, and the treatment costs were calculated to evaluate the economy of each JAKi. Appropriateness was described based on literature review and drug labels. Accessibility of three oral JAKi was assessed by using a questionnaire survey. The innovation of JAKi was elucidated from the perspective of its mechanism of action. RESULTS In terms of safety, the incidence of upper respiratory tract infection (OR=1.47, 95%CI of 1.04-2.08, P=0.03) and nasopharyngitis (OR=1.44, 95%CI of 1.06-1.95, P=0.02) in the upadacitinib 30 mg group was significantly higher than that in the placebo group; the incidence of nasopharyngitis in baricitinib 4 mg group was significantly higher than that in the placebo group (OR=2.24, 95%CI of 1.39-3.61, P=0.000 8) and baricitinib 2 mg group (OR=0.48, 95%CI of 0.31-0.74,P=0.001). In terms of efficacy, regardless of the dosage, all three JAKi groups were superior to the placebo group, and the high-dose groups of upadacitinib and abrocitinib were superior to the low-dose groups (P<0.000 1). In terms of economy, the annual treatment cost of baricitinib was the lowest (13 870.0 yuan), but it has not been approved for atopic dermatitis indication in China; next was upadacitinib (27 192.5 yuan). In terms of appropriateness, the overall appropriateness of the three JAKis was good, but none of them was suitable for patients with severe liver injury. In terms of accessibility, baricitinib had the highest availability rate (59.4%), but the affordability of upadacitinib was relatively good under China’s medical insurance system. In terms of innovation, among the three types of JAKi, upadacitinib and abrocitinib had better innovation. CONCLUSIONS Three oral JAKi treatments for atopic dermatitis have controllable safety and good efficacy. Considering the issue of medical insurance reimbursement, it is recommended that Chinese patients use upadacitinib.